DOI: 10.1055/s-00000069

Seminars in Liver Disease

References

Cooksley WG, Piratvisuth T, Wang YJ. et al.
40 kDa peginterferon alfa-2A (PEGASYS): efficacy and safety results from a phase II, randomized actively controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B 
Hepatology 2001; 34: 349A-349A  

Download Bibliographical Data

Search in: